High-risk individuals who test positive for COVID-19 and who have had mild to moderate symptoms for no longer than 10 days from onset of symptoms may qualify for monoclonal antibody treatment.
Monoclonal Antibodies (mAb) help the immune system recognize and respond more effectively to COVID-19. In high-risk patients, mAb treatment has been shown to decrease the severity of COVID-19 symptoms and reduce the rate of hospitalization.*
mAb treatment has the most clinical benefit during the earliest stages of infection. All those who receive a positive COVID-19 molecular test result through QuestDirect will be contacted by PWNHealth to evaluate eligibility and, if appropriate, prescribe treatment.
The FDA has issued an emergency use authorization (EUA) to permit mAb products for the treatment of mild-to-moderate COVID-19.
*Monoclonal Antibodies for High-Risk COVID-19 Positive Patients | combatCOVID.hhs.gov